PL1951661T3 - Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania - Google Patents

Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania

Info

Publication number
PL1951661T3
PL1951661T3 PL06850109T PL06850109T PL1951661T3 PL 1951661 T3 PL1951661 T3 PL 1951661T3 PL 06850109 T PL06850109 T PL 06850109T PL 06850109 T PL06850109 T PL 06850109T PL 1951661 T3 PL1951661 T3 PL 1951661T3
Authority
PL
Poland
Prior art keywords
preparation
receptor antagonists
therapeutic uses
glucagon receptor
glucagon
Prior art date
Application number
PL06850109T
Other languages
English (en)
Inventor
Scott Eugene Conner
Jianke Li
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1951661T3 publication Critical patent/PL1951661T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL06850109T 2005-11-17 2006-11-07 Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania PL1951661T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73762705P 2005-11-17 2005-11-17
PCT/US2006/060586 WO2007106181A2 (en) 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses
EP06850109A EP1951661B1 (en) 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
PL1951661T3 true PL1951661T3 (pl) 2012-12-31

Family

ID=38474434

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06850109T PL1951661T3 (pl) 2005-11-17 2006-11-07 Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania

Country Status (14)

Country Link
US (1) US7696248B2 (pl)
EP (1) EP1951661B1 (pl)
JP (1) JP5107253B2 (pl)
CN (1) CN101309895B (pl)
AU (1) AU2006340002B2 (pl)
BR (1) BRPI0618349A2 (pl)
CA (1) CA2629348C (pl)
CY (1) CY1113159T1 (pl)
DK (1) DK1951661T3 (pl)
ES (1) ES2391109T3 (pl)
PL (1) PL1951661T3 (pl)
PT (1) PT1951661E (pl)
SI (1) SI1951661T1 (pl)
WO (1) WO2007106181A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551015A (en) * 2004-06-14 2010-07-30 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2009220615B2 (en) * 2008-03-05 2013-12-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
AR073412A1 (es) 2008-10-03 2010-11-03 Schering Corp Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
CL2009001796A1 (es) * 2009-02-06 2011-09-16 Takeda Pharmaceuticals Co Compuestos derivados de heteroarilo-(benceno/heteroarilo) fusionados con actividad antagonista de glucagon; composicion farmaceutica; y su uso para suprimir la produccion de azucar y para la terapia o el tratamiento de la diabetes.
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
SG191040A1 (en) * 2010-12-23 2013-08-30 Pfizer Glucagon receptor modulators
WO2012107850A1 (en) * 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN103547563B (zh) * 2011-05-23 2016-03-23 詹森药业有限公司 可用作胰高血糖素受体拮抗剂的联苯基衍生物
PT2714661E (pt) * 2011-05-23 2016-01-22 Janssen Pharmaceutica Nv Derivados de ácido picolinamido propanóico úteis como antagonistas do recetor de glucagona
EP2734503B1 (en) * 2011-07-22 2015-09-16 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JPWO2013147026A1 (ja) * 2012-03-29 2015-12-14 武田薬品工業株式会社 芳香環化合物
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP2016052300A (ja) * 2014-09-03 2016-04-14 日立化成株式会社 生体物質捕獲システム
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
CA2373892A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2003048109A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Novel glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
WO2004056763A2 (en) 2002-12-20 2004-07-08 Novo Nordisk A/S Novel glucagon antagonists
EP1863755A1 (en) 2005-03-21 2007-12-12 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives

Also Published As

Publication number Publication date
US20080300308A1 (en) 2008-12-04
PT1951661E (pt) 2012-09-19
CN101309895B (zh) 2012-10-03
AU2006340002B2 (en) 2011-12-22
CA2629348C (en) 2013-08-13
BRPI0618349A2 (pt) 2011-08-23
CY1113159T1 (el) 2016-04-13
EP1951661A2 (en) 2008-08-06
WO2007106181A3 (en) 2007-12-06
JP5107253B2 (ja) 2012-12-26
EP1951661B1 (en) 2012-08-08
CA2629348A1 (en) 2007-09-20
US7696248B2 (en) 2010-04-13
CN101309895A (zh) 2008-11-19
AU2006340002A1 (en) 2007-09-20
SI1951661T1 (sl) 2012-11-30
WO2007106181A2 (en) 2007-09-20
DK1951661T3 (da) 2012-09-03
ES2391109T3 (es) 2012-11-21
JP2009519226A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
SI1951661T1 (sl) Antagonisti glukagonskega receptorja priprava interapevtske uporabe
PL1951658T3 (pl) Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne
TWI346553B (en) Chemokine receptor antagonists
AP2007004218A0 (en) NPY antagonists, preparation and use
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
IL190686A0 (en) Il-21 receptor antagonists
IL179462A0 (en) Use of the receptor gpr86
IL180682A0 (en) N-hydroxamide derivatives, their preparation and use
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
EP1808446A4 (en) IL-18 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION WITH THE ANTAGONIST
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
EP1812008A4 (en) ANTAGONISTS OF THE IL-8 RECEPTOR
IL190519A0 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
PL1951659T3 (pl) Antagoniści receptora glukagonu, wytwarzanie i zastosowania terapeutyczne
GB0414798D0 (en) Receptor
GB0525029D0 (en) Receptor Antagonist
GB0413872D0 (en) Receptor
IL190836A0 (en) Cxc-chemokine antagonists, their preparation and use
GB0427025D0 (en) Receptor
GB0417119D0 (en) Receptor
GB0413096D0 (en) Receptor
GB0404584D0 (en) Receptor